VolitionRX (VNRX) Registration filing summary

Company overview and business model

• Multi-national epigenetics company developing blood tests for early detection and monitoring of diseases like cancer and sepsis.

• Product portfolio includes Nu.Q® Vet (for companion animals), Nu.Q® NETS (for NETosis-related diseases), Nu.Q® Discover, and cancer-focused diagnostics.

• Operations span Belgium, California, London, and Nevada, with approximately 60 employees.

• Collaborates with academic, clinical, and industry partners globally.

Financial performance and metrics

• Issued secured convertible notes totaling $9.9 million in 2025 and 2026, with associated warrants.

• Imposed additional 10% penalty on outstanding principal due to market capitalization covenant breach in May 2026.

• May face liquidity challenges if unable to generate sufficient cash flow to service debt.

Use of proceeds and capital allocation

• Will not receive any proceeds from the sale of shares by the selling stockholder; all proceeds go to the selling stockholder.

• Responsible for registration expenses, excluding brokerage commissions.